Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2010
09/21/2010US7799760 Use of pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention
09/21/2010US7799759 albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins
09/21/2010US7799758 Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
09/21/2010US7799757 Treatment of osteoporosis, for the promotion of bone formation or for the inhibition of bone loss; genetic engineering; side effect reduction
09/21/2010US7799756 reacting an acetyl cyclosporin aldehyde with an organozirconium reagent (Cp2Zr(H)Cl) to provide acetyl cyclosporin diene (the acetate of trans ISATX247) and deacetylating the acetyl cyclosporin diene to produce the trans-isomer of ISATX247; immunosuppressant
09/21/2010US7799755 Stimulating a Th2 response by administering multivalent LNFPIII, an immunomodulatory glycan Lacto-N-Fucopentaose III, which contains the Lewis X trisaccharide (CD!%/antigen/); autoimmune disease; antidiabetic agents; antiarthritic agents; multiple sclerosis; colitis; psoriasis
09/21/2010US7799754 Compositions and methods for treating bone
09/21/2010US7799753 Bisubstrate inhibitors of protein tyrosine kinases as therapeutic agents
09/21/2010US7799549 Methods for increasing protein polyethylene glycol (PEG) conjugation
09/21/2010US7799541 for Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock and sepsis related to cardiac dysfunction
09/21/2010US7799533 Polypeptides, their production and use
09/21/2010US7799529 Nephrin gene and protein
09/21/2010US7799527 selecting a treatment for a desired synthesized polymer species; useful for automated selection of treatments for synthetic reaction products
09/21/2010US7799349 Isolating autologous mononuclear cells and transplanting locally into injured tissue
09/21/2010US7799348 animal extracts comprising protein hydrozylates, hydrolyzed type II collagen, used for inducing cartilage formation, prohylaxis of connective tissue disorders and replenishing skin viscoelasticity; wound healing agents
09/21/2010US7799344 coating crystalline microparticles such as fumaryl diketopiperazine with active agent by altering surface properties of particles to facilitate favorable association on particle by active agent; surface properties include electrostatic, hydrophobic, hydrogen bonding properties; for drug delivery to lungs
09/21/2010US7799330 comprises claimed amino acid sequence or an immunogenic fragment thereof wherein the protein elicits production of antibodies that interfere with invasion by Babesia bovis into erythrocytes
09/21/2010US7799329 Viruses for the treatment of cellular proliferative disorders
09/21/2010US7799326 Methods and compositions for cathespin k complex-mediated disorders
09/21/2010US7799323 Using interleukin-31(IL-31) agonist for treatment and prevention of allergic rhinitis
09/21/2010US7799322 Use of IL-6 in liver injury
09/21/2010CA2445068C Azo compounds for type i phototherapy
09/21/2010CA2408746C Antisense phosporodiamidate morpholino oligonucleotide inhibition of cytochrome p450 to modulate drug pharmacokinetics
09/21/2010CA2404235C Cell-specific adenovirus vectors comprising an internal ribosome entry site
09/21/2010CA2384880C Methods for making recombinant proteins using apoptosis inhibitors
09/21/2010CA2370493C Peptides and assays for the diagnosis of lyme disease and compositions useful for the prevention thereof
09/21/2010CA2367457C Protein for blocking platelet adhesion
09/21/2010CA2361081C Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis
09/21/2010CA2345659C Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties
09/21/2010CA2343074C Akt nucleic acids, polypeptides, and uses thereof
09/21/2010CA2330241C Attenuated pestiviruses
09/21/2010CA2309356C Novel exendin agonist compounds
09/21/2010CA2307142C N-terminally chemically modified protein compositions and methods
09/21/2010CA2306692C Dipeptide apoptosis inhibitors and the use thereof
09/21/2010CA2251655C In vivo gene transfer methods for wound healing
09/21/2010CA2234941C Delivery of biologically active polypeptides
09/21/2010CA2225788C Therapeutic agents and autoimmune diseases
09/21/2010CA2225675C Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
09/21/2010CA2211578C Muscle protein proteolysis inhibiting agent containing il-6 receptor antibody
09/16/2010WO2010105263A1 Use of hasf as a protective agent against ischemic tissue damage
09/16/2010WO2010105191A2 Antimicrobial compositions and methods of use therefore
09/16/2010WO2010105188A2 Methods and systems for hemostasis using cryotherapy
09/16/2010WO2010105160A2 Method of treating hematological malignancies and hematological neoplasms
09/16/2010WO2010105097A2 Sparc angiogenic domain and methods of use
09/16/2010WO2010105081A1 Method of treating heart failure
09/16/2010WO2010104961A1 Treatment methods for autoimmune disorders
09/16/2010WO2010104959A1 Treatment and diagnostic methods for hypersensitive disorders
09/16/2010WO2010104854A2 Immunomodulatory therapeutic agents
09/16/2010WO2010104821A1 Mirac proteins
09/16/2010WO2010104790A2 Fatty-acid based particles
09/16/2010WO2010104576A1 Methods for treating joints and discs with a carrier matrix and cells
09/16/2010WO2010104341A2 Compositions for diagnosis of fungal infections
09/16/2010WO2010104176A1 Mega-phosphoprotein cleavage inhibitor
09/16/2010WO2010104147A1 Antioxidant agent
09/16/2010WO2010104114A1 Method for preparing polypeptide library
09/16/2010WO2010103959A1 Ameliorating agent for chronic obstructive pulmonary disease
09/16/2010WO2010103837A1 Progression inhibitor or prophylactic agent for atherosclerosis, blood cholesterol level-lowering agent, and functional food or food for specified health uses
09/16/2010WO2010103708A1 Dipeptide having antiatherosclerotic action
09/16/2010WO2010103515A2 Compositions and methods for prevention and treatment of neurodegenerative diseases
09/16/2010WO2010103475A2 Use of serine protease inhibitors in the treatment of neutropenia
09/16/2010WO2010103292A2 A genotyping tool for improving the prognostic and clinical management of ms patients
09/16/2010WO2010103291A2 Treatment of diseases related to hyperactivity of the complement system
09/16/2010WO2010103254A1 Peptide promoting cell adhesion and migration
09/16/2010WO2010103204A1 Metal ion chelating agents, methods for preparing same and uses thereof
09/16/2010WO2010103137A1 Industrial production of recombinant lysosomal enzymes in insect larvae
09/16/2010WO2010103119A1 Compositions and methods for elimination of gram-negative bacteria
09/16/2010WO2010103070A2 Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
09/16/2010WO2010103045A1 Treatment of diabetes and metabolic syndrome
09/16/2010WO2010103038A1 Interleukin-21 variants having antagonistic binding to the il-21 receptor
09/16/2010WO2010102983A1 Methods for the treatment or prevention of systemic sclerosis
09/16/2010WO2010102886A1 Modification of factor viii
09/16/2010WO2010102762A1 Oil-based preparation containing antiprotozoal triazines and anthelmintic cyclodepsipeptides
09/16/2010WO2010102518A1 Polymer of fusion proteins
09/16/2010WO2010102387A1 Interleukin-12 polymorphisms for identifying risk for primary biliary cirrhosis
09/16/2010WO2010102380A1 Potent vegf antagonists
09/16/2010WO2010102337A1 Injectable biomaterials
09/16/2010WO2010088411A3 Conformationally dynamic peptides
09/16/2010WO2010085648A3 Methods for reducing radiation-induced tissue damage
09/16/2010WO2010079047A3 Octreotide depot formulation with constantly high exposure levels
09/16/2010WO2010062762A3 Compositions and methods for reducing the signs of aging of the skin
09/16/2010WO2010062399A8 Csf1r extracellular domain fusion molecules and treatments using same
09/16/2010WO2010059706A3 Translation factors as anti-aging drug targets
09/16/2010WO2010057596A3 New therapy and medicament using integrin ligands for treating cancer
09/16/2010WO2010057242A3 Vaccine
09/16/2010WO2010056981A3 Methods and compositions for regulating iron homeostasis by modulation bmp-6
09/16/2010WO2010052563A3 Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
09/16/2010WO2009003034A8 Oligopeptide tyrosinase inhibitors and uses thereof
09/16/2010US20100235935 Plasma anti-diabetic nucb2 peptide (pladin) and uses thereof
09/16/2010US20100235931 Novel Neurological Function of mPKCI
09/16/2010US20100234966 Bone repair or augmentation device
09/16/2010US20100234417 Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers
09/16/2010US20100234308 Wake-up remedy
09/16/2010US20100234307 Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
09/16/2010US20100234306 Use of a peptide as a therapeutic agent
09/16/2010US20100234305 Polymeric delivery formulations of leuprolide with improved efficacy
09/16/2010US20100234304 Beta sheet tapes ribbons in tissue engineering
09/16/2010US20100234303 Agents, methods and uses
09/16/2010US20100234302 Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus
09/16/2010US20100234301 Methods and Compositions for the Treatment of Gastrointestinal Disorders
09/16/2010US20100234300 A purified pro-cytolytic peptide; used to treat localized and metastatic prostate cancer; administered intratumorally and/or intraprostatically
1 ... 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 ... 3163